Table 2.
Baseline characteristics and demographic data (ITT population)
| Characteristic | C.E.R.A. (n = 162) | Darbepoetin alfa (n = 162) |
|---|---|---|
| Male, n (%) | 70 (43) | 80 (49) |
| Mean (SD) age, yr | 63.9 (14.1) | 66.9 (12.8) |
| Mean (SD) weight, kg | 76.8 (16.2) | 80.5 (19.5) |
| Mean (SD) Hb, g/dl | 10.2 (0.6) | 10.2 (0.7) |
| Mean (SD) CrCl, ml/min | 27.7 (9.7)a | 27.0 (10.7) |
| Mean (SD) C-reactive protein, mg/L | 6.5 (11.1)b | 7.0 (14.2) |
| Mean (SD) albumin, g/L | 39.4 (5.2)c | 38.3 (5.3)d |
| Median (IQR) TSAT (%) | 23.7 (20.0–30.7)a | 23.7 (20.3–29.3)a |
| Median (IQR) ferritin, μg/L | 174.7 (107.7–271.3) | 185.8 (129.0–284.4) |
| Iron supplementation at baseline, % | 55 | 54 |
| Mean (SD) SBP, mmHg | 139 (18.9)a | 139 (20.9)a |
| Mean (SD) DBP, mmHg | 73 (10.5)a | 72 (10.7)a |
| Cause of renal failure %, | ||
| diabetes | 45 | 49 |
| hypertension/large vessel disease | 40 | 44 |
| glomerulonephritis | 9 | 12 |
| interstitial nephritis/pyelonephritis | 6 | 6 |
| undefined cause | 7 | 3 |
| polycystic kidney disease | 4 | 6 |
| secondary glomerulonephritis/vasculitis | 1 | 2 |
| other hereditary/congenital diseases | 1 | 1 |
| Previous and concomitant antihypertensive treatments, % | ||
| angiotensin-converting enzyme inhibitors | 51 | 48 |
| calcium channel blockers | 39 | 40 |
| β adrenoceptor antagonists | 39 | 40 |
| angiotensin II receptor blockers | 37 | 35 |
| Race, % | ||
| white | 70 | 81 |
| black | 22 | 12 |
| Asian | 4 | 6 |
| other | 4 | 2 |
| Ethnicity, % | ||
| Hispanic | 10 | 10 |
| non-Hispanic | 90 | 90 |
| Geographic region, % | ||
| United States | 35 | 36 |
| outside United States | 65 | 64 |
IQR, interquartile range.
a
n = 161 patients with evaluable measurements.
b
n = 159 patients with evaluable measurements.
c
n = 158 patients with evaluable measurements.
d
n = 160 patients with evaluable measurements.